Martin Shkreli refuses to testify, still infuriates with a smile

WASHINGTON -- Pharmaceutical chief Martin Shkreli refused to testify Thursday in an appearance before U.S. lawmakers over severe hikes for a drug sold by a company that he acquired, yet even without answering questions, managed to leave them infuriated.

See Full Article

Shkreli appeared to smirk throughout his hour-long appearance, and moments afterward, insulting tweets began to appear under his official account calling the lawmakers "imbeciles."

Shkreli, widely scorned for hiking the price of a long-established and potentially lifesaving drug by more than 5,000 per cent, exercised his Fifth Amendment right against self-incrimination when he went before the House Oversight and Government Reform Committee.

Four times the brash entrepreneur and former hedge fund manager -- who has been unapologetic about the price hikes, intoned before the committee, "On the advice of counsel I invoke my Fifth amendment privilege against self-incrimination and respectfully decline to answer your question."

Lawmakers erupted in fury. Rep. Elijah Cummings of Maryland, the top Democrat on the committee, told the 32-year-old Shkreli to wipe the smirk off his face.

"I call this money blood money ... coming out of the pockets of hardworking Americans," he said, as Shkreli sat through the lecture. "I know you are smiling, but I am very serious, sir," Cummings said. "I truly believe you can become a force of tremendous good. All I ask is that you reflect on it. No, I don't ask, I beg that you reflect on it. "

Shkreli was dismissed less than an hour into the hearing, but not before Chairman Rep. Jason Chaffetz, R-Utah. shouted down a request by Shkreli's attorney to speak. Lawmakers, instead, took turns denouncing his conduct and attitude.

Minutes after Shkreli walked out of the room on his official Twitter account appeared the message, "Hard to accept that these imbeciles represent the people in our government."

Hard to accept that these imbeciles represent the people in our government.

— Martin Shkreli (@MartinShkreli) February 4, 2016

It could not immediately be confirmed if those tweets were written by Shkreli.

Cummings, attributing them to Shkreli, boiled over. "There are very real issues for people with compromised immune systems," he thundered as he asked Turing executive Nancy Retzlaff to interpret the messages on Shkreli's Twitter account.

Shkreli faces separate criminal charges of securities fraud in connection with another drug company he owned

The lawmakers had summoned him to answer for the decision that made him infamous: raising the price for Daraprim, the only approved drug for a rare and sometimes deadly parasitic infection.

Shkreli, who pleaded not guilty after his arrest in December in New York, has been out on $5 million bail. He walked into the packed hearing room well before the session began and met the crush of cameras. Even a few members of the House panel were swept up in the curiosity and snapped Shkreli's photo on their cellphones.

Also appearing before the lawmakers was Turing's chief commercial officer and the interim CEO of Canada's largest drugmaker, Valeant Pharmaceuticals. Documents from Valeant and Turing show they have made a practice of buying and then dramatically raising prices for, low-cost drugs given to patients with life-threatening conditions including heart disease, AIDS and cancer, according to excerpts released this week by the House panel.

The two companies' executives insisted they were committed to ensuring that cost isn't a deterrent for patients who need the drugs.

With Shkreli mum, it was up to Retzlaff to defend the Daraprim price rise. She said about 3,000 people are treated by Daraprim, and only 25 per cent are covered by commercial insurance. She added that the overall impact of the drug on the budget of commercial health plans "is very, very small."

Documents show how executives at both companies planned to maximize profits while fending off negative publicity over the price hikes.

Presentations by Turing executives, part of the trove of documents obtained by the panel., show that as early as last May, the company planned to turn Daraprim into a $200-million-a-year drug by dramatically increasing its price. Turing bought the 60-year-old drug from Impax Laboratories in August for $55 million and swiftly raised its price.

Shkreli said in an email to one contact: "We raised the price from $1,700 per bottle to $75,000. Should be a very handsome investment for all of us."

But anticipating a possible backlash, the company warned in an internal memo that advocates for HIV patients might react to the price hike.

Valeant likewise identified revenue goals first and then used drug prices to reach them, committee staff said in a memo. It said Valeant believed it could repeatedly raise the prices of Nitropress and Isuprel without repercussions because they're administered by hospitals, which are less price-sensitive than consumers.

Valeant used patient assistance programs to distract attention and justify its price hikes, according to the memo.

AP Business Writer Tom Murphy in Indianapolis contributed to this report



Advertisements

Latest Economic News

  • Wireless wars heat up as big telcos top up phone plans with bonus data

    Economic CBC News
    Wireless wars are heating up again with numerous telcos offering smartphone plans topped up with what many Canadians crave — extra data. The standout deals are in Manitoba where Rogers began the battle this week by doubling the data — at no extra cost — for its 10 GB and 15 GB family phone plans. Source
  • Unions representing CP Rail workers issue notice of strike action

    Economic CTV News
    LAVAL, Que. -- The unions representing train operators and signalling workers at Canadian Pacific Railway Ltd. have served the company with notice of a strike action. The Teamsters Canada Rail Conference and the International Brotherhood of Electrical Workers have told CP Rail they will be in a position to strike as of 10 p.m. Source
  • CP Rail union formally serves strike notice

    Economic CBC News
    The strike notice comes a day after the Teamsters Canada Rail Conference rejected the company's latest contract offer. "After workers at CP voted to reject the last contract offers, the company is still refusing to negotiate seriously," the statement said. Source
  • Loonie sinks to two-week low: Is this the start of another big drop?

    Economic CBC News
    The Canadian dollar fell to a two-week low against the U.S. dollar on Friday as lower oil prices and global trade tensions continue to weigh on the currency. The loonie is already down more than three per cent this year and was at 77.11 cents US on Friday. Source
  • What Trump's proposed auto tariff could mean for Canada

    Economic CBC News
    As with many of the trade actions announced by the Trump administration, the possible effects of his proposed Section 232 investigation of vehicle imports are both menacing and unclear. To understand how it might affect Canada, one first has to know how the Trump administration intends to define an "imported car. Source
  • WestJet agrees to 'settlement process' with pilots union

    Economic CBC News
    Anxious air travellers can now rest easy with the threat of a WestJet strike seemingly at an end. On Friday evening, WestJet and the Air Line Pilots Association agreed to a settlement process through the Federal Mediation and Conciliation Service. Source
  • WestJet, pilot's union agree to settlement process with mediator

    Economic CTV News
    CALGARY -- The threat of a strike by WestJet pilots appears to be over. The Calgary-based airline and the union that represents the pilots said Friday they have agreed to a settlement process that will involve a federal mediator. Source
  • Canada's pot industry gets a new supporter: Snoop Dogg

    Economic CTV News
    MONTREAL -- Canada is more advanced than the United States regarding its approach to cannabis, world-famous rapper and weed entrepreneur Snoop Dogg said Friday to a crowd of hundreds at Montreal's C2 technology conference. The entertainer lamented that in the U.S. Source
  • Energy sector weighs on Canadian markets as oil drops below US$70 a barrel

    Economic CBC News
    Canada's main stock index continued to fall Friday as the price for oil moved below US$70 a barrel and further dragged down the important energy sector. "Today, oil is by far the major story," said Macan Nia, a senior investment strategist at Manulife Investments. Source
  • Mercer International to give up TSX listing following loss at NAFTA tribunal

    Economic CBC News
    Mercer International says it intends to voluntarily de-list from the Toronto Stock Exchange on June 11, about three months after it lost a six-year-old NAFTA battle with the Canadian government. The U.S.-based forest products company had mounted a $250-million claim against the Canadian government in early 2012. Source